CliffBio
small molecule

ABILIFY

ARIPIPRAZOLE

Loss of exclusivity—loss of exclusivity
CompanyOtsuka Pharmaceutical →See this company's full patent-cliff portfolio

Drug detail

Brand nameABILIFY
Active ingredientARIPIPRAZOLE
Strength9.75MG/1.3ML (7.5MG/ML)
Dosage formINJECTABLE
RouteINTRAMUSCULAR
ModalitySmall molecule
FDA approvalSeptember 2006
Marketing statusDISCN

More from Otsuka Pharmaceutical

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.